AstraZeneca scraps another GLP-1 candidate against type 2 diabetes
Two months after dropping one of its GLP-1 agonists, AstraZeneca has decided to scrap another – leaving none left in the company’s clinical pipeline.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.